Symbols / XRTX
XRTX Chart
About
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy. It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance. The company is based in Calgary, Canada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.72M |
| Enterprise Value | 1.58M | Income | -1.94M | Sales | — |
| Book/sh | 0.38 | Cash/sh | 0.17 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -1.11 | PEG | — |
| P/S | — | P/B | 1.03 | P/C | — |
| EV/EBITDA | -0.65 | EV/Sales | — | Quick Ratio | 1.45 |
| Current Ratio | 1.62 | Debt/Eq | 2.99 | LT Debt/Eq | — |
| EPS (ttm) | -0.40 | EPS next Y | -0.35 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-26 | ROA | -45.32% |
| ROE | -94.63% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 6.96M |
| Shs Float | 6.25M | Short Float | 0.03% | Short Ratio | 0.06 |
| Short Interest | — | 52W High | 1.41 | 52W Low | 0.38 |
| Beta | 0.15 | Avg Volume | 145.56K | Volume | 17.91K |
| Target Price | $14.07 | Recom | None | Prev Close | $0.40 |
| Price | $0.39 | Change | -3.18% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$14.06
Mean price target
2. Current target
$0.39
Latest analyst target
3. DCF / Fair value
$-6.04
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.39
Low
$14.06
High
$14.06
Mean
$14.06
- Huge gout genetics study highlights target in kidney disease research - Stock Titan Wed, 31 Dec 2025 08
- XORTX Therapeutics Inc. (XRTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade Fri, 17 Oct 2025 14
- XRTX Stock Surges Over 40% on Bold Move to Snag Promising Kidney Treatment Tech - RagingBull Fri, 17 Oct 2025 07
- Kidney drug deal: XORTX gets more time to close Vectus buy - Stock Titan Wed, 04 Feb 2026 08
- Breakout Move: Is XRTX stock undervalued right now - Market Activity Summary & AI Forecasted Entry/Exit Points - baoquankhu1.vn Sun, 22 Feb 2026 03
- XORTX Therapeutics stock soars after acquiring renal therapeutic program - Investing.com Nigeria Fri, 17 Oct 2025 07
- Will XRTX stock split again soon - Quarterly Profit Review & Breakout Confirmation Trade Signals - mfd.ru Wed, 18 Feb 2026 08
- XORTX Announces Pricing of US$1.1 Million Registered Direct Offering - Yahoo Finance ue, 21 Oct 2025 07
- TipRanks - Google Initiates XORTX Therapeutics(XRTX.US) With Sell Rating, Announces Target Price $0.48 - 富途牛牛 Sun, 01 Feb 2026 08
- Xortx Therapeutics: Micro-cap roller coaster as XRTX tests the patience of speculative biotech inves - AD HOC NEWS Wed, 21 Jan 2026 08
- 1,746,631 shares at $0.63: XORTX (NASDAQ: XRTX) prices registered direct offering - Stock Titan ue, 21 Oct 2025 07
- XRTX Stock Price and Chart — TSXV:XRTX - TradingView Fri, 05 Nov 2021 09
- $3.0M Acquisition: XORTX Secures VB4‑P5 Renal Anti‑Fibrotic Program from Vectus, Pre‑IND - Stock Titan Fri, 17 Oct 2025 07
- What’s the beta of XRTX stock - Market Growth Review & Real-Time Buy Signal Notifications - mfd.ru Wed, 11 Feb 2026 20
- XORTX (NASDAQ: XRTX) gets $1.00 bid-price notice; 180-day window, listing intact - Stock Titan Mon, 20 Oct 2025 07
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | — | — | — | Davies Foss (Krysta) | Director of Issuer | — | 2025-12-31 00:00:00 | D | nan |
| 1 | 3654 | — | Disposition in the public market at price 1.00 per share. | Van Damme (Paul Joseph) | Director of Issuer | — | 2025-10-17 00:00:00 | D | 3650.0 |
| 2 | 3132 | — | Disposition in the public market at price 0.98 per share. | Van Damme (Paul Joseph) | Director of Issuer | — | 2025-10-17 00:00:00 | D | 3081.0 |
| 3 | 8191 | — | Acquisition in the public market at price 0.74 per share. | Davidoff, Allen Warren | Director of Issuer | — | 2025-07-22 00:00:00 | D | 6020.0 |
| 4 | 300 | — | Acquisition in the public market at price 0.87 per share. | Davidoff, Allen Warren | Director of Issuer | — | 2025-06-23 00:00:00 | D | 262.0 |
| 5 | 500 | — | Acquisition in the public market at price 0.86 per share. | Davidoff, Allen Warren | Director of Issuer | — | 2025-06-23 00:00:00 | D | 429.0 |
| 6 | 2000 | — | Acquisition in the public market at price 1.02 per share. | Davidoff, Allen Warren | Director of Issuer | — | 2025-05-14 00:00:00 | D | 2040.0 |
| 7 | 2000 | — | Acquisition in the public market at price 1.02 per share. | Davidoff, Allen Warren | Director of Issuer | — | 2025-05-14 00:00:00 | D | 2044.0 |
| 8 | 1000 | — | Acquisition in the public market at price 0.73 per share. | Davidoff, Allen Warren | Director of Issuer | — | 2025-05-12 00:00:00 | D | 733.0 |
| 9 | 300 | — | Acquisition in the public market at price 1.04 per share. | Davidoff, Allen Warren | Director of Issuer | — | 2025-05-12 00:00:00 | D | 313.0 |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -4.68M | -9.54M | -12.70M | -4.23M |
| TotalUnusualItems | 683.07K | 3.63M | 2.47M | 1.34M |
| TotalUnusualItemsExcludingGoodwill | 683.07K | 3.63M | 2.47M | 1.34M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -3.31M | -2.16M | -7.72M | -1.58M |
| ReconciledDepreciation | 117.27K | 139.69K | 58.15K | 14.27K |
| EBITDA | -4.00M | -5.91M | -10.23M | -2.90M |
| EBIT | -4.12M | -6.05M | -10.29M | -2.91M |
| NetInterestIncome | 121.91K | 253.54K | 103.59K | -4.45K |
| InterestExpense | 0.00 | 4.39K | ||
| InterestIncome | 101.37K | |||
| NormalizedIncome | -4.00M | -5.79M | -10.19M | -2.92M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -3.31M | -2.16M | -7.72M | -1.58M |
| TotalExpenses | 4.12M | 6.05M | 10.29M | 2.91M |
| DilutedAverageShares | 2.88M | 1.98M | 1.48M | 1.09M |
| BasicAverageShares | 2.88M | 1.98M | 1.48M | 1.09M |
| DilutedEPS | -1.15 | -1.09 | -4.71 | -1.20 |
| BasicEPS | -1.15 | -1.09 | -4.71 | -1.20 |
| DilutedNIAvailtoComStockholders | -3.31M | -2.16M | -7.72M | -1.58M |
| NetIncomeCommonStockholders | -3.31M | -2.16M | -7.72M | -1.58M |
| NetIncome | -3.31M | -2.16M | -7.72M | -1.58M |
| NetIncomeIncludingNoncontrollingInterests | -3.31M | -2.16M | -7.72M | -1.58M |
| NetIncomeContinuousOperations | -3.31M | -2.16M | -7.72M | -1.58M |
| PretaxIncome | -3.31M | -2.16M | -7.72M | -1.58M |
| OtherIncomeExpense | 683.07K | 3.63M | 2.47M | 1.34M |
| SpecialIncomeCharges | -279.03K | 0.00 | -926.46K | -1.29M |
| ImpairmentOfCapitalAssets | 0.00 | |||
| RestructuringAndMergernAcquisition | 279.03K | 0.00 | 926.46K | 1.29M |
| GainOnSaleOfSecurity | 962.10K | 3.63M | 3.39M | 2.62M |
| NetNonOperatingInterestIncomeExpense | 121.91K | 253.54K | 103.59K | -4.45K |
| TotalOtherFinanceCost | -121.91K | -253.54K | -103.59K | 4.45K |
| InterestExpenseNonOperating | 0.00 | 4.39K | ||
| InterestIncomeNonOperating | 101.37K | |||
| OperatingIncome | -4.12M | -6.05M | -10.29M | -2.91M |
| OperatingExpense | 4.12M | 6.05M | 10.29M | 2.91M |
| OtherOperatingExpenses | 1.53M | 1.26M | 1.07M | 602.57K |
| DepreciationAmortizationDepletionIncomeStatement | 117.27K | 139.69K | 58.15K | 14.27K |
| DepreciationAndAmortizationInIncomeStatement | 117.27K | 139.69K | 58.15K | 14.27K |
| Amortization | 31.07K | 66.63K | 17.08K | 14.27K |
| AmortizationOfIntangiblesIncomeStatement | 31.07K | 66.63K | 17.08K | 14.27K |
| DepreciationIncomeStatement | 86.20K | 73.06K | 41.07K | 0.00 |
| ResearchAndDevelopment | 183.83K | 2.42M | 6.76M | 677.58K |
| SellingGeneralAndAdministration | 2.28M | 2.23M | 2.40M | 1.62M |
| GeneralAndAdministrativeExpense | 2.28M | 2.23M | 2.40M | 1.62M |
| OtherGandA | 1.99M | 1.93M | 1.79M | 1.17M |
| SalariesAndWages | 290.67K | 300.39K | 610.51K | 445.79K |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 3.48M | 2.00M | 1.67M | 1.44M |
| ShareIssued | 3.48M | 2.00M | 1.67M | 1.44M |
| TotalDebt | 38.78K | 11.51K | 77.60K | 0.00 |
| TangibleBookValue | 3.15M | 4.47M | 6.80M | 13.00M |
| InvestedCapital | 3.34M | 4.64M | 7.00M | 13.20M |
| WorkingCapital | 1.92M | 3.24M | 9.38M | 15.36M |
| NetTangibleAssets | 3.15M | 4.47M | 6.80M | 13.00M |
| CapitalLeaseObligations | 38.78K | 11.51K | 77.60K | 0.00 |
| CommonStockEquity | 3.34M | 4.64M | 7.00M | 13.20M |
| TotalCapitalization | 3.34M | 4.64M | 7.00M | 13.20M |
| TotalEquityGrossMinorityInterest | 3.34M | 4.64M | 7.00M | 13.20M |
| StockholdersEquity | 3.34M | 4.64M | 7.00M | 13.20M |
| OtherEquityInterest | 6.06M | 5.49M | 6.22M | 5.02M |
| GainsLossesNotAffectingRetainedEarnings | -52.60K | -52.60K | -52.60K | 75.54K |
| OtherEquityAdjustments | -52.60K | -52.60K | -52.60K | 75.54K |
| RetainedEarnings | -21.17M | -17.85M | -15.70M | -7.98M |
| CapitalStock | 18.49M | 17.06M | 16.52M | 16.09M |
| CommonStock | 18.49M | 17.06M | 16.52M | 16.09M |
| TotalLiabilitiesNetMinorityInterest | 757.99K | 825.94K | 5.38M | 4.18M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 3.87M | 3.63M |
| DerivativeProductLiabilities | 531.00K | 3.85M | 3.63M | |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 11.51K | 0.00 | |
| LongTermCapitalLeaseObligation | 0.00 | 11.51K | 0.00 | |
| CurrentLiabilities | 757.99K | 825.94K | 1.51M | 552.95K |
| OtherCurrentLiabilities | 572.00K | 531.00K | ||
| CurrentDebtAndCapitalLeaseObligation | 38.78K | 11.51K | 66.09K | |
| CurrentCapitalLeaseObligation | 38.78K | 11.51K | 66.09K | 0.00 |
| PayablesAndAccruedExpenses | 147.21K | 283.43K | 1.45M | 552.95K |
| CurrentAccruedExpenses | 63.19K | 87.61K | 151.41K | 228.99K |
| Payables | 84.02K | 195.81K | 1.29M | 323.96K |
| AccountsPayable | 84.02K | 195.81K | 1.29M | 323.96K |
| TotalAssets | 4.09M | 5.47M | 12.37M | 17.38M |
| TotalNonCurrentAssets | 1.42M | 1.40M | 1.48M | 1.47M |
| NonCurrentAccountsReceivable | 1.20M | 1.20M | 1.19M | 1.27M |
| GoodwillAndOtherIntangibleAssets | 183.11K | 175.25K | 199.83K | 202.12K |
| OtherIntangibleAssets | 183.11K | 175.25K | 199.83K | 202.12K |
| NetPPE | 34.72K | 23.93K | 92.68K | 0.00 |
| AccumulatedDepreciation | -200.21K | -114.00K | -40.94K | 0.00 |
| GrossPPE | 234.93K | 137.93K | 133.62K | 0.00 |
| OtherProperties | 23.34K | 23.34K | 19.03K | |
| BuildingsAndImprovements | 211.59K | 114.59K | 114.59K | 0.00 |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 2.68M | 4.07M | 10.90M | 15.91M |
| CurrentDeferredAssets | 0.00 | 323.44K | 0.00 | 0.00 |
| PrepaidAssets | 185.41K | 236.97K | 379.62K | 1.00M |
| Receivables | 17.64K | 60.71K | 81.75K | 40.65K |
| AccountsReceivable | 17.64K | 60.71K | 81.75K | 40.65K |
| CashCashEquivalentsAndShortTermInvestments | 2.47M | 3.45M | 10.43M | 14.87M |
| CashAndCashEquivalents | 2.47M | 3.45M | 10.43M | 14.87M |
| CashEquivalents | 2.42M | 3.35M | 6.61M | 0.00 |
| CashFinancial | 53.69K | 95.00K | 3.82M | 14.87M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -3.72M | -6.63M | -8.21M | -4.83M |
| RepaymentOfDebt | -69.72K | -66.09K | -20.41K | 0.00 |
| IssuanceOfCapitalStock | 3.50M | 0.00 | 5.00M | 18.07M |
| CapitalExpenditure | -38.92K | -46.36K | -45.70K | -31.81K |
| EndCashPosition | 2.47M | 3.45M | 10.43M | 14.87M |
| BeginningCashPosition | 3.45M | 10.43M | 14.87M | 134.52K |
| EffectOfExchangeRateChanges | -35.95K | 4.04K | -136.15K | 195.86K |
| ChangesInCash | -938.06K | -6.99M | -4.30M | 14.54M |
| FinancingCashFlow | 2.78M | -361.04K | 3.91M | 19.37M |
| CashFlowFromContinuingFinancingActivities | 2.78M | -361.04K | 3.91M | 19.37M |
| NetOtherFinancingCharges | -667.88K | -295.25K | -1.07M | -698.58K |
| ProceedsFromStockOptionExercised | 16.57K | 296.00 | 64.00 | 2.00M |
| NetCommonStockIssuance | 3.50M | 0.00 | 5.00M | 18.07M |
| CommonStockIssuance | 3.50M | 0.00 | 5.00M | 18.07M |
| NetIssuancePaymentsOfDebt | -69.72K | -66.09K | -20.41K | 0.00 |
| NetLongTermDebtIssuance | -69.72K | -66.09K | -20.41K | 0.00 |
| LongTermDebtPayments | -69.72K | -66.09K | -20.41K | 0.00 |
| InvestingCashFlow | -38.92K | -46.36K | -45.70K | -31.81K |
| CashFlowFromContinuingInvestingActivities | -38.92K | -46.36K | -45.70K | -31.81K |
| NetIntangiblesPurchaseAndSale | -38.92K | -42.05K | -26.00K | -31.81K |
| PurchaseOfIntangibles | -38.92K | -42.05K | -26.00K | -31.81K |
| NetPPEPurchaseAndSale | 0.00 | -4.31K | -19.70K | 0.00 |
| PurchaseOfPPE | 0.00 | -4.31K | -19.70K | 0.00 |
| OperatingCashFlow | -3.68M | -6.58M | -8.17M | -4.80M |
| CashFlowFromContinuingOperatingActivities | -3.68M | -6.58M | -8.17M | -4.80M |
| ChangeInWorkingCapital | 116.79K | -1.03M | 1.47M | -1.08M |
| ChangeInPayablesAndAccruedExpense | -134.45K | -1.19M | 892.26K | -259.32K |
| ChangeInPrepaidAssets | 208.17K | 142.65K | 622.60K | -794.71K |
| ChangeInReceivables | 43.07K | 21.04K | -41.10K | -29.38K |
| ChangesInAccountReceivables | 43.07K | 21.04K | -41.10K | -29.38K |
| OtherNonCashItems | 3.70K | 59.09K | ||
| StockBasedCompensation | 122.53K | 120.98K | 487.94K | 396.42K |
| ProvisionandWriteOffofAssets | 0.00 | 0.00 | ||
| AssetImpairmentCharge | 0.00 | 0.00 | ||
| DepreciationAmortizationDepletion | 117.27K | 139.69K | 58.15K | 14.27K |
| DepreciationAndAmortization | 117.27K | 139.69K | 58.15K | 14.27K |
| AmortizationCashFlow | 31.07K | 66.63K | 17.08K | 14.27K |
| AmortizationOfIntangibles | 31.07K | 66.63K | 17.08K | 14.27K |
| Depreciation | 86.20K | 73.06K | 41.07K | |
| OperatingGainsLosses | -721.90K | -3.66M | -2.47M | -2.61M |
| GainLossOnInvestmentSecurities | -756.07K | -3.64M | -2.46M | -2.64M |
| NetForeignCurrencyExchangeGainLoss | 34.18K | -13.63K | -6.39K | 28.26K |
| NetIncomeFromContinuingOperations | -3.31M | -2.16M | -7.72M | -1.58M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for XRTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|